Title : Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting.

Pub. Date : 2020 May 1

PMID : 31948999






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Recent FDA approvals of regimens targeting programmed death 1 (PD-1) in combination with anti-CTLA-4 or with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) are reshaping front-line therapy for metastatic kidney cancer. Tyrosine vascular endothelial growth factor A Homo sapiens
2 Recent FDA approvals of regimens targeting programmed death 1 (PD-1) in combination with anti-CTLA-4 or with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) are reshaping front-line therapy for metastatic kidney cancer. Tyrosine vascular endothelial growth factor A Homo sapiens